Deposition of small particles in the developing lung - 02/04/12
, Michael T. Newhouse 2 
Corresponding author. Tel.: +972 46828712; fax: +972 46828647.Summary |
Infancy is a time of marked and rapid changes in respiratory tract development. Infants (0–1 year of age) and young children (1– 3 years of age) are a unique subpopulation with regard to therapeutic aerosols. Anatomical, physiological and emotional factors, peculiar to these age groups, present significant challenges for aerosol delivery to the respiratory tract. Most studies with inhaled corticosteroids (ICS) have administered aerosols with relatively large particles, frequently > 3μm in mass median aerodynamic diameter (MMAD). These drugs were designed for use in adults and older children and were administered with masks which were frequently rejected by children under age 3-4 years. We review the reasons that large-particle aerosols are likely to be less effective in infants and young children. We suggest that the benefit of inhaled medications in this age group requires further evaluation to determine if better therapeutic outcomes might be achieved using smaller particles and more patient-friendly delivery systems.
Le texte complet de cet article est disponible en PDF.Abbreviations : ICS, URT, LRT, CFC, HFA, MMAD, CF, MDI, VHC
Keywords : Small particle aerosols, asthma, infants, nebulizers, inhalers, corticosteroids
Plan
 | No potential conflict of interest relevant to this article was reported by any of the authors.. |
Vol 13 - N° 2
P. 73-78 - juin 2012 Retour au numéro
Article précédent
- Nanoparticles and Children’s Lungs: is there a need for caution?
- Peter D. Sly, Karen Schüepp
- Airborne Engineered Nanoparticles: Potential Risks and Monitoring Challenges for Assessing their Impacts on Children
- G. Biskos, A. Schmidt-Ott
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?